一种Rhamnose-PEG-修改的树突聚合物,用于长期有效的通过皮肤递送药物
Haoyuan Song1, Yu Cai2, Longyi Nan2
1Department of Pharmaceutical Sciences, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
ACS applied materials & interfaces
|February 21, 2024
概括
一种新型的树化压力敏感粘合剂 (PSA),TMPE@Rha,增强凝聚力和组织粘合力,用于通过皮肤递送药物. 这种先进的PSA符合FDA的标准,提供卓越的性能和生物相容性.
科学领域:
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
- 聚合物化学 聚合物化学
背景情况:
- 传统的压力敏感粘合剂 (PSA) 面临美国食品和药物管理局 (FDA) 对通过皮肤递送药物系统的审查.
- 现有的PSA通常在凝聚力,组织粘附和长期皮肤兼容性方面表现出局限性.
- 需要先进的PSA来改善药物负载,增强透性,并确保生物相容性.
研究的目的:
- 介绍和表征一种新型的树枝化压力敏感粘合剂,TMPE@Rha,用于通过皮肤递送药物.
- 与传统的PSA相比,评估TMPE@Rha的增强凝聚力,组织粘附性和药物输送能力.
- 为了确认材料的生物相容性和遵守FDA对透皮应用的要求.
主要方法:
- 使用拉姆诺斯,三西和聚乙烯甘醇的TMPE@Rha的配方).
- 对猪皮,木材和人类皮肤基板的剥皮强度的评估.
- 评估粘附时间和人类皮肤上的"暗环"现象.
- 用迪克洛芬雅克进行药物加载和释放研究.
- 在体外透性和显微镜分析.
- 生物相容性测试.生物相容性测试.
主要成果:
- 在猪和木质基板上,TMPE@Rha的剥离强度比标准的烯酸PSA高5到6倍.
- 持续强烈的人体皮肤粘附超过7天,没有"暗环"效应.
- 装有迪克洛芬的TMPE@Rha表现出比商业替代品大3.12倍的剥离强度,保持粘附时间长达6天.
- 证实含有拉姆诺斯可增强相互作用强度和表面链的移动性.
- 在体外研究表明,药物加载,分发和皮肤透性得到改善.
- 生物相容性测试证实TMPE@Rha没有刺激性.
结论:
- TMPE@Rha代表了压力敏感粘合剂的重大进步,用于通过皮肤递送药物,提供卓越的附着性和强度.
- 这种新型配方符合甚至超过了FDA的标准,为传统的PSA提供了安全有效的替代品.
- TMPE@Rha为高度粘性,含有药物的PSA设定了一个新的基准,为下一代透皮系统铺平了道路.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...